Abstract
Severe acute respiratory syndrome coronavirus has infected over 114 million people worldwide as of March 2021, with worldwide mortality rates ranging between 1-10%. We use information on up to 421,111 UK Biobank participants to identify possible predictors for long-term susceptibility to severe COVID-19 infection (N =1,088) and mortality (N =376). We include 36,168 predictors in our analyses and use a gradient boosting decision tree (GBDT) algorithm and feature attribution based on Shapley values, together with traditional epidemiological approaches to identify possible risk factors. Our analyses show associations between socio-demographic factors (e.g. age, sex, ethnicity, education, material deprivation, accommodation type) and lifestyle indicators (e.g. smoking, physical activity, walking pace, tea intake, and dietary changes) with risk of developing severe COVID-19 symptoms. Blood (cystatin C, C-reactive protein, gamma glutamyl transferase and alkaline phosphatase) and urine (microalbuminuria) biomarkers measured more than 10 years earlier predicted severe COVID-19. We also confirm increased risks for several pre-existing disease outcomes (e.g. lung diseases, type 2 diabetes, hypertension, circulatory diseases, anemia, and mental disorders). Analyses on mortality were possible within a sub-group testing positive for COVID-19 infection (N =1,953) with our analyses confirming association between age, smoking status, and prior primary diagnosis of urinary tract infection.
SUMMARY Our hypothesis-free approach combining machine learning with traditional epidemiological methods finds a number of risk factors (sociodemographic, lifestyle, and psychosocial factors, biomarkers, disease outcomes and treatments) associated with developing severe COVID-19 symptoms and COVID-19 mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Australian National Health and Medical Research Foundation (NHMRC), grant number 1123603.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank project was approved by North West Multicenter Research Ethics Committee and the National Information Governance Board for Health and Social Care (11/NW/0382).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos